Kathryn Stiede brings 30 years of clinical operations experience to eGenesis, where her core responsibility is the development of clinical strategy and execution for all products. In addition, Kathryn supports the eGenesis scientific team with academic collaborations and donor production.
Her career in industry spans large pharma to biotech start-ups as well as numerous therapeutic indications. Ms. Stiede began her career at SmithKline Beecham/GSK where she progressed through roles in sales and clinical development in anti-infectives and biologics. In 2002, she became Director of Clinical Operations for Transkaryotic Therapies, working in rare genetic glycosomal storage diseases. Prior to her role at eGenesis, she served as Senior Director of Clinical Operations at Nimbus Therapeutics, where she played a key role in the company’s NASH program. Her therapeutic area experience includes cardiovascular, neuropsychology, oncology, respiratory and autoimmune indications.
Ms. Stiede received her B.S. from Illinois State University.